Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: Chemical. CAS: 29702-43-0. Formula: C6H11FO5. MW: 182.15. 2-Fluoro-2-deoxy-D-glucose [FDG] is a glucose analog that inhibits cellular glycosylation. It is the natural isotope-form of 18F-FDG that can be taken up by cells but does not undergo metabolic glycolysis. FDG uptake is closely related to the expression of the glucose transporter (GLUT) in malignant tumours. FDG is also a substrate of hexokinase isozymes and an inhibitor of cellular glycosylation. FDG is taken up by high-glucose-using cells such as brain, brown adipocytes, kidney and cancer cells, where phosphorylation prevents the glucose from being released again from the cell, once it has been absorbed. The 2-hydroxyl group (OH) in normal glucose is needed for further glycolysis (metabolism of glucose by splitting it), but FDG is missing this 2-hydroxyl and cannot be further metabolized in cells. FDG is used in positron emission tomography (PET) as contrast agent and is the most widely used PET marker. FDG-PET can be used for diagnosis, staging, and monitoring treatment of cancers, particularly in Hodgkin's disease, non-Hodgkin lymphoma, colorectal cancer, breast cancer, melanoma, and lung cancer. FDG has also anticancer and chemosensitizing activity.
Alerte
Veuillez saisir les champs obligatoires! |